PT - JOURNAL ARTICLE AU - Eugenia Toledo-Romaní, María AU - García-Carmenate, Mayra AU - Valenzuela-Silva, Carmen AU - Baldoquín-Rodríguez, Waldemar AU - Martínez-Pérez, Marisel AU - Rodríguez-González, Meiby AU - Paredes-Moreno, Beatriz AU - Mendoza-Hernández, Ivis AU - González-Mujica, Raúl AU - Samón-Tabio, Oscar AU - Velazco-Villares, Pablo AU - Bacallao-Castillo, Juan Pablo AU - Licea-Martín, Ernesto AU - Rodríguez-Ortega, Misladys AU - Herrera-Marrero, Nuris AU - Caballero-González, Esperanza AU - Egües-Torres, Liudmila AU - Duartes-González, Reinaldo AU - García-Blanco, Serguey AU - Pérez-Cabrera, Suzette AU - Huete-Ferreira, Santos AU - Idalmis-Cisnero, Kirenia AU - Fonte-Galindo, Omayda AU - Meliá-Pérez, Dania AU - Rojas-Remedios, Ivonne AU - Doroud, Delaram AU - Gouya, Mohammad Mehdi AU - Biglari, Alireza AU - Van der Stuyft, Patrick AU - Fernández-Castillo, Sonsire AU - Climent-Ruiz, Yanet AU - Valdes-Balbín, Yury AU - García-Rivera, Dagmar AU - Verez-Bencomo, Vicente AU - the SOBERANA Phase 3 team TI - Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial AID - 10.1101/2021.10.31.21265703 DP - 2022 Jan 01 TA - medRxiv PG - 2021.10.31.21265703 4099 - http://medrxiv.org/content/early/2022/08/03/2021.10.31.21265703.short 4100 - http://medrxiv.org/content/early/2022/08/03/2021.10.31.21265703.full AB - Background SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoid). Phases 1/2 clinical trials demonstrated high immunogenicity, promoting neutralizing IgG and specific T-cell response. A third heterologous dose of SOBERANA-Plus (RBD-dimer) further increased neutralizing antibodies.Methods From March 8th to September 30th, 2021 we conducted in Havana, Cuba a multicentre randomized, double-blind, placebo-controlled, phase-3 trial evaluating two doses of SOBERANA-02 and a heterologous scheme with one dose SOBERANA-Plus added to it. Participants 19–80 years were randomly assigned to receiving 28 days apart either the two or three dose scheme or placebo. The main endpoint was vaccine efficacy in preventing the occurrence of RT-PCR confirmed symptomatic COVID-19 occurring at least 14 days after the second or third dose in the per-protocol population. We also assessed efficacy against severe disease and, in all participants receiving at least one vaccine/placebo dose, safety for 28 days after each dose.Finding We included 44·031 participants in a context of Beta VOC predominance, with this variant being gradually replaced by Delta near the trial end. Vaccine efficacy in the heterologous combination was 92·0% (95%CI 80·4–96·7) against symptomatic and 100% against severe COVID-19. Two doses of SOBERANA-02 was 69·7% (95%CI 56·5-78·9) and 74·9% (95%CI 33·7-90·5) efficacious to protect against symptomatic and severe COVID-19, respectively. The occurrence of serious and severe AEs was very rare and equally distributed between placebo and vaccine groups. Solicited AEs were slightly more frequent in the vaccine group but predominantly local and mostly mild and transient.Interpretation Our results indicate that the straightforward to manufacture SOBERANA vaccines are efficacious in a context of Beta and Delta VOC dominance and that they constitute an attractive, feasible option for low- and middle-income countries, where besides financial constraints ease of vaccine storage and distribution is of concern.Funding This study received funds from Finlay Vaccine Institute and National Fund for Science and Technology (FONCI-CITMA-Cuba, contract 2020–20). of Ministry of Science, Technology and the Environment (Contract Project-2020-20) in Cuba.Competing Interest Statement(M. M. P, M. C. R. G., B. P. M., R. G.M. R., E. L. M., E.C.G., S. F., Y. C., Y. V.B., D. G.R., V. V. B.) are from Finlay Vaccine Institute the sponsor of the trialClinical TrialRPCEC00000354 International Clinical Trials Registry Platform. IdentifierFunding StatementSupported by Finlay Vaccine Institute, Biocubafarma and by Fondo Nacional de Ciencia y Tecnica (FONCI-CITMA-Cuba, contract 2020-20).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Central Research Ethics Committee from the Cuban Ministry of Health was ad hoc appointed for this trial. They approved the protocol (Clinical Trials IFV/COR/09 number, RPCEC00000354) and the consent forms.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://rpcec.sld.cu/en/trials/RPCEC00000354-En